ICON has expanded its U.S. and UK bioanalytical facilities for biomarker and cell-based assay services. The company increased its bioanalytical labs in Whitesboro, NY and Manchester, UK, by 7,000 and 4,000 sq. ft., respectively. The expansions house dedicated immunoassay labs at each facility for biomarker testing and cell-based assays.
“We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors,” said Brian O’Dwyer, senior vice president of Global Bioanalytical Services, ICON Development Solutions. “In particular, the expansion of our dedicated biomarker testing laboratories allows us to support biomarker development programs across multiple testing platforms globally.”